Ironwood Pharmaceuticals (IRWD) investor relations material

Executive summary

• Achieved 97% year-over-year growth in LINZESS U.S. net sales, reaching $273 million in Q1 2026, driven by improved net price and 5% prescription demand growth.

• GAAP net income was $40.8 million in Q1 2026, reversing a net loss of $37.4 million in Q1 2025, with adjusted EBITDA at $76.7 million.

• Advanced apraglutide clinical development for SBS-IF, with STARS-2 Phase III trial site initiations on track for Q2 2026.

• LINZESS remains the prescription leader for IBS-C and CIC, with ongoing efforts to expand pediatric indications and global commercialization.

• Maintained full-year 2026 financial guidance and expects strong operating cash flows to support debt repayment.

Financial highlights

• Q1 2026 total revenue was $106.5 million, up from $41.1 million in Q1 2025.

• U.S. net sales of LINZESS reached $272.5 million, a 97% increase year-over-year.

• U.S. brand collaboration revenue was $104.2 million, up 169% from Q1 2025.

• Commercial margin on LINZESS sales improved to 76% from 52% year-over-year.

• Ended Q1 with $220.5 million in cash and cash equivalents and $105.8 million in accounts receivable.

Outlook and guidance

• Full-year 2026 guidance: LINZESS U.S. net sales of $1.125–$1.175 billion, total revenue $450–$475 million, and adjusted EBITDA greater than $300 million.

• Expect low single-digit percentage LINZESS prescription demand growth for the year.

• Plan to repay 2026 convertible note in cash at maturity in June, with year-end total debt expected at ~$300 million, less than 1x expected 2026 adjusted EBITDA.

• Cash, expected operating inflows, and borrowing capacity projected to cover operating needs for at least the next twelve months.

• No material business development expenses assumed for 2026.